[{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"65e8d7c8-cd05-4be4-b31d-3d804c0d4afd","acronym":"NCI-2009-01173","url":"https://clinicaltrials.gov/study/NCT00843882","created_at":"2023-11-21T16:15:34.542Z","updated_at":"2025-02-25T16:43:32.520Z","phase":"Phase 3","brief_title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","source_id_and_acronym":"NCT00843882 - NCI-2009-01173","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTPRC • CDC25C • GNRP","pipe":"","alterations":" ","tags":["PTPRC • CDC25C • GNRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Retacrit (epoetin alfa-epbx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 01/29/2009","start_date":" 01/29/2009","primary_txt":" Primary completion: 07/08/2019","primary_completion_date":" 07/08/2019","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"7918a7a6-96c5-4624-85f3-798790d9ac5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06703944","created_at":"2025-02-26T10:34:57.875Z","updated_at":"2025-02-26T10:34:57.875Z","phase":"","brief_title":"Risk Model for Metastasis Detection of Neuroblastoma","source_id_and_acronym":"NCT06703944","lead_sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" PTPRC • NCAM1 • CD81","pipe":"","alterations":" ","tags":["PTPRC • NCAM1 • CD81"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 500","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-04"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"dd45a77d-d5a4-4150-b58b-a6b91ace8084","acronym":"","url":"https://clinicaltrials.gov/study/NCT04513028","created_at":"2021-01-18T21:37:49.532Z","updated_at":"2024-07-02T16:35:01.212Z","phase":"","brief_title":"Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma","source_id_and_acronym":"NCT04513028","lead_sponsor":"Kelly McMasters","biomarkers":" IFNG • TNFA • PTPRC • ITGAM","pipe":" | ","alterations":" IFNG expression","tags":["IFNG • TNFA • PTPRC • ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-24"},{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"},{"id":"1d4dd198-7dd9-44b5-bf2f-70642e346bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06400160","created_at":"2024-05-11T04:34:11.020Z","updated_at":"2024-07-02T16:35:05.740Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","source_id_and_acronym":"NCT06400160","lead_sponsor":"Twinpig Biolab, Inc.","biomarkers":" CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2","pipe":" | ","alterations":" IL2-L","tags":["CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-06"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"e57f47ff-f3fa-4c75-8521-b468c593cb9d","acronym":"PNN-CP","url":"https://clinicaltrials.gov/study/NCT06244355","created_at":"2024-02-06T15:20:12.068Z","updated_at":"2024-07-02T16:35:12.227Z","phase":"","brief_title":"Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer","source_id_and_acronym":"NCT06244355 - PNN-CP","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PTPRC","pipe":"","alterations":" ","tags":["PTPRC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-29"},{"id":"99a93edf-b954-4a4c-b660-2bb38fc9221e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05809128","created_at":"2023-04-12T14:03:12.772Z","updated_at":"2024-07-02T16:35:13.058Z","phase":"","brief_title":"Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging","source_id_and_acronym":"NCT05809128","lead_sponsor":"IRCCS SYNLAB SDN","biomarkers":" CD8 • PTPRC • NCAM1 • CD14","pipe":"","alterations":" ","tags":["CD8 • PTPRC • NCAM1 • CD14"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-25"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"7465a53d-edcc-499b-8a80-50f901ea6413","acronym":"HO147SMM","url":"https://clinicaltrials.gov/study/NCT03673826","created_at":"2021-01-18T18:01:13.776Z","updated_at":"2024-07-02T16:35:30.805Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","source_id_and_acronym":"NCT03673826 - HO147SMM","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-11-01"},{"id":"8a4f4c76-2dc0-425a-a17a-009310b1b1fb","acronym":"IELSG37","url":"https://clinicaltrials.gov/study/NCT01599559","created_at":"2021-01-18T06:50:23.394Z","updated_at":"2024-07-02T16:35:32.505Z","phase":"Phase 3","brief_title":"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma","source_id_and_acronym":"NCT01599559 - IELSG37","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20 • TNFRSF8 • BCL6 • PTPRC • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 12/17/2029","study_completion_date":" 12/17/2029","last_update_posted":"2023-10-19"},{"id":"03e171ea-fd7a-443f-8eec-206fb38f17b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06044506","created_at":"2023-09-21T15:10:40.830Z","updated_at":"2024-07-02T16:35:35.783Z","phase":"Phase 1","brief_title":"Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma","source_id_and_acronym":"NCT06044506","lead_sponsor":"Dr Cipto Mangunkusumo General Hospital","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-09-26"},{"id":"99fd1b20-e5d8-4f4e-b908-4bdb8158c160","acronym":"SIERRA","url":"https://clinicaltrials.gov/study/NCT02665065","created_at":"2021-01-18T12:59:29.161Z","updated_at":"2024-07-02T16:35:42.652Z","phase":"Phase 3","brief_title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT02665065 - SIERRA","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" HLA-DRB1 • PTPRC • HLA-B • HLA-C","pipe":" | ","alterations":" PTPRC expression","tags":["HLA-DRB1 • PTPRC • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTPRC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • doxorubicin hydrochloride • azacitidine • cyclophosphamide • Iomab-B (I-131-apamistamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-07-19"},{"id":"dbd11893-864b-4376-84f5-eae0c9d3bb0a","acronym":"LILIPSY","url":"https://clinicaltrials.gov/study/NCT05810402","created_at":"2023-04-12T14:03:29.425Z","updated_at":"2024-07-02T16:35:49.977Z","phase":"","brief_title":"Liver Cancer and Immunotherapy in the Liquid Biopsy Era","source_id_and_acronym":"NCT05810402 - LILIPSY","lead_sponsor":"University Hospital, Montpellier","biomarkers":" PTPRC","pipe":" | ","alterations":" PD-L1 expression","tags":["PTPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-04-20"},{"id":"4440793a-ab83-4b82-b144-f3e5b46b6fe3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05748704","created_at":"2023-03-01T15:01:57.757Z","updated_at":"2024-07-02T16:35:54.508Z","phase":"Phase 1","brief_title":"Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients","source_id_and_acronym":"NCT05748704","lead_sponsor":"University of Genova","biomarkers":" CD8 • IL6 • TNFA • IL2RA • PTPRC • IGF1 • NCAM1 • ENTPD1 • IGFBP3 • IL1B • IGFBP1 • ISG20 • LEP","pipe":"","alterations":" ","tags":["CD8 • IL6 • TNFA • IL2RA • PTPRC • IGF1 • NCAM1 • ENTPD1 • IGFBP3 • IL1B • IGFBP1 • ISG20 • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-03-01"},{"id":"d7250f67-4645-4aee-9249-1bb54b6cd454","acronym":"TANOs","url":"https://clinicaltrials.gov/study/NCT04867421","created_at":"2021-04-30T11:55:07.437Z","updated_at":"2024-07-02T16:36:09.921Z","phase":"","brief_title":"Neutrophils in Bone Sarcomas","source_id_and_acronym":"NCT04867421 - TANOs","lead_sponsor":"Université de Reims Champagne-Ardenne","biomarkers":" PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-05-25"},{"id":"72054b88-e010-49a7-be72-9a0192b14916","acronym":"","url":"https://clinicaltrials.gov/study/NCT04709458","created_at":"2021-01-19T20:52:10.272Z","updated_at":"2024-07-02T16:36:11.112Z","phase":"Phase 1","brief_title":"Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis","source_id_and_acronym":"NCT04709458","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" PTPRC","pipe":"","alterations":" ","tags":["PTPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-2400"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2022-05-03"},{"id":"0f196312-39a4-4784-97b3-69fcc7a694c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00329030","created_at":"2021-01-18T01:08:08.536Z","updated_at":"2024-07-02T16:36:21.719Z","phase":"Phase 3","brief_title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","source_id_and_acronym":"NCT00329030","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD20 • CD8 • IL2RA • PTPRC • NCAM1 • ISG20","pipe":"","alterations":" ","tags":["CD20 • CD8 • IL2RA • PTPRC • NCAM1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 224","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2021-11-01"},{"id":"b1fc3749-e95d-4a68-ab16-6259c58fc366","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011097","created_at":"2021-08-18T14:53:35.366Z","updated_at":"2024-07-02T16:36:26.202Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05011097","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Y150"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2021-08-18"},{"id":"9c287f66-8773-4060-b201-60ea917c26d4","acronym":"GEMMK","url":"https://clinicaltrials.gov/study/NCT03123276","created_at":"2021-01-18T15:23:24.090Z","updated_at":"2025-02-25T16:06:04.944Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma","source_id_and_acronym":"NCT03123276 - GEMMK","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" PD-L1 • CD8 • PD-1 • PTPRC • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • PTPRC • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 02/05/2023","primary_completion_date":" 02/05/2023","study_txt":" Completion: 02/05/2023","study_completion_date":" 02/05/2023","last_update_posted":"2021-06-30"}]